参考文献/References:
1 Haugen BR, Larson LL, Pugazhenthi U, et al. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab, 2004, 89(1):272-280.
2 Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma:a comprehensive review. Endocr Relat Cancer, 2005, 12(1):49-64.
3 Jarzab B, Handidewicz-Junak D, Roskosz J, et al. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma:a single-centre study of 54 patients. Eur J Nucl Mad Mol Imaging, 2003, 30(8):1077-1086.
4 Luster M, Lassmann M, Haenscheid H, et al. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab, 2000, 85(10):3640-3645.
5 Berg G, Lindstedt G, Suurkula M, et al. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest, 2002, 25(1):44-52.
6 de Keizer B, Hoekstra A, Konijnenberg MW, et al. Bone marrow dosimetry and safety of high 131Ⅰ activities given after recom-binant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. J Nucl Med, 2004, 45(9):1549-1554.
7 Gruning T, Tiepolt C, Zophel K, et al. Retinoic acid for redifferentiation of thyroid cancer-does it hold its promise?. Eur J Endocrinol, 2003, 148(4):395-402.
8 Zarnegar R, Bmnaud L, Kanauchi H, et al. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using trichostatin A, a histone deacetylase inhibitor.Surgery, 2002, 132(6):984-990.
9 Pancini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi 131Ⅰ:a comparison in thyroid cancer pa-tients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab, 2002, 87(9):4063-4068.
10 Bobbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as preparation for radioiodine thyroid remnant ablation. J Nucl Med, 2002, 43(11):1482-1488.
11 Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer, effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metsb, 2003, 88(9):4110-4115.
12 Lippi F, Capezzone M, Angelini F, et al. Radioiodine treatment of meta static differentiated thyroid cancer in patients on L-thyroxine,using recombinant human TSK Eur J Endocrinol, 2001, 144(1):5-11.
13 Pellegriti G, Scollo C, Giuffrida D, et al. Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer. Thyroid, 2001, 11(11):1025-1030.
14 Kovatcheva RD, Hadjieva TD, Kirilov GG, et al. Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer. Nucl Med Rev Cent East Eur, 2004, 7(1):13-19.
15 Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab, 1999, 84(11):3877-3885.
16 Mazzaferri EL, Massoll N. Management of papillary and follicular(differentiated) thyroid cancer:, new paradigms using recombinant human thyrotropin. Endocr Relat Cancer, 2002, 9(4):227-247.
17 Schmutzler C, Hoang-Vu C, Ruger B, et al. Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses. Eur J Endocrinol, 2004, 150(4):547-556.
18 Schmutzler C, Kohrle J. Retinoic acid redifferentialion therapy for thyroid cancer. Thyroid, 2000, 10(5):393-406.
19 Dadachova E, Carrasco N. The Na/I symporter (NLS):imaging and therapeutic applications. Semin Nucl Med, 2004, 34(1):23-31.
20 Kurebayashi J, Tanaka K, Otsuki T, et al. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1. J Clin Endocrinol Metab, 2000, 85(8):2889-2896.
21 Hoang-Vu C, Bull K, Schwarz I, et al. Regulation of CD97 protein in thyroid carcinoma. J Clin Endocrinol Metab, 1999, 84(3):1104-1109.
22 Simon D, Korber C, Krausch M, et al. Clinical impact of retinoids in redifferenfiation therapy of advanced thyroid cancer:final results of a pilot study. Eur J Nucl Mad Mol Imaging, 2002, 29(6):775-782.
23 Short SC, Suovuori A, Cook G, et al. A phase Ⅱ study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin Oncol, 2004, 16(8):569-574.
24 Kitazono M, Robey R, Zhan Z, et al. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab, 2001, 86(7):3430-3435.
25 Kitazono M, Bates S, Fok P, et al. The histone deacetylese inhibitor FR901228(desipeptide) restores expression and function of pseudo-null p53. Cancer Bid Ther, 2002, 1(6):665-668.
26 Imanishi R, Ohtsuru A, Iwamatsu M, et al. A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy. J Clin Endocrinol Metab, 2002, 87(10):4821-4824.
相似文献/References:
[1]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[4]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
[5]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[6]刘鹏杰,唐铭,邓智勇,等.131I治疗儿童分化型甲状腺癌期间出现低钙血症伴癫痫发作一例[J].国际放射医学核医学杂志,2015,39(4):352.[doi:10.3760/cma.j.issn.1673-4114.2015.04.017]
[7]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[8]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
[9]李莉,晋建华,陆克义,等.131I去除分化型甲状腺癌术后残留甲状腺组织疗效的meta分析[J].国际放射医学核医学杂志,2014,38(3):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
Li Li,Jin Jianhua,Lu Keyi,et al.A meta-analysis of efficacy of iodine-131 for post-thyroidectomy ablation of remnants in patients with differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):152.[doi:10.3760/cma.j.issn.1673-4114.2014.03.003]
[10]李永军,徐兆强,柳卫,等.分化型甲状腺癌术后131I治疗患者胸腺生理性摄取131I的临床研究[J].国际放射医学核医学杂志,2014,38(4):227.[doi:10.3760/cma.j.issn.1673-4114.2014.04.005]
Li Yongjun,Xu Zhaoqiang,Liu Wei,et al.Clinical research on physiological thymic uptake of 131I in post-operative patients with differentiated thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):227.[doi:10.3760/cma.j.issn.1673-4114.2014.04.005]
[11]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[12]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(6):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[13]程维维,王辉.促甲状腺激素受体与甲状腺癌关系的研究进展[J].国际放射医学核医学杂志,2012,36(2):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]
CHENG Wei-wei,WANG Hui.Progress in the relationship of thyroid-stimulating hormone receptor and thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):69.[doi:10.3760/cma.j.issn.1673-4114.2012.02.002]